Seroprevalence of hepatitis B surface antigenemia and its effects on hematological parameters in pregnant women in Osogbo, Nigeria

Virology Journal

Anthony I Okoh³  Timothy Sibanda³  Daniel A Adekanle²  Abideen A Wahab¹  Olatunji M Kolawole³ 

[1] Department of Biological Sciences, Osun State University, P.M.B 4494, Osogbo, Nigeria;Department of Obstetrics and Gynaecology, LAUTECH Teaching Hospital, Osogbo, Nigeria;Applied and Environmental Microbiology Research Group (AEMREG), Department of Biochemistry and Microbiology, University of Fort Hare, Alice, South Africa

关键词: Risk factors;    Hematological parameters;    Hepatitis B surface antigen;    Enzyme-linked immunosorbent assay;   

Others  :  1152600
DOI  :  10.1186/1743-422X-9-317

 received in 2011-11-22, accepted in 2012-12-17,  发布年份 2012

【 摘 要 】

Background

The transmission of the hepatitis B virus (HBV) is parenteral, sexual and perinatal. Prevention of vertical transmission of HBV is extremely important because HBV infection in early life usually results in a chronic carrier State.

Methods

A descriptive seroepidemiological study of hepatitis B virus and its effects on hematological parameters was investigated in pregnant women attending antenatal clinic of LAUTECH Teaching Hospital, Osogbo, Nigeria. 200 venous samples were subjected to full blood count and its sera were subjected to enzyme–linked immunosorbent assay for the detection of surface antigen of hepatitis B virus.

Results

Prevalence rate of 16.5% was obtained for hepatitis B surface antigen in pregnant women. The highest HBsAg prevalence rate recorded was 23.3% for pregnant women between aged 30–34 years while the lowest recorded was zero percent for those aged greater than 40 years. RBC, WBC, neutrophil, hemoglobin lymphocyte and platelet counts have no significant effects on HBsAg positivity of pregnant women (p = 0.801). There was no significant difference in HBsAg positivity in relation to maternal age, gravidity, gestational age, family type, level of education and occupation (p = 0.073). Among the potential risk factors, there was significant difference in HBsAg positivity in the pregnant women in relation to their history of HBV vaccination (p = 0.039).

Conclusions

We advocate universal free screening of pregnant women as the endemicity of HBV infections is thus being propagated.

【 授权许可】

   
2012 Kolawole et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]CDC: Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2002, 51(RR-6):1-78.
• [2]WHO: Advanced immunization management. Hepatitis. Fact sheet No. 2005.
• [3]Redd HT, Baunbach H, Kohn W: Patient to patient transmission of hepatitis B virus associated with oral Surgery. J infect Dis 2007, 195(9):1311-4.
• [4]CDC: Hepatitis transmitted by a human bite. Morb. Mort. Wkly Rep; 1974:23-24.
• [5]ACIP: Protection against viral hepatitis: recommendation of the immunization practices advisory committee. Morb Mort Wkly Rep 1990., 39(RR-2)
• [6]Nacos B, Dao B, Dahourou M, et al.: HBs antigen carrier state in pregnant women in Bobo Dioulasso (Burkinafaso). Dakar Med 2000, 42(2):188-190.
• [7]Edmund WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ: Epidemiological patterns of hepatitis B virus (HBV) infection in highly endemic areas. Epidemiol Infect 1996, 313-325.
• [8]Fakunle YM, Abdulraham MB, Whittel HC: Hepatitis B virus infection in children and adults in northern Nigeria: a preliminary survey. Trans R Soc Trop Med Hyg 1981, 75(5):625-629.
• [9]Christy NE, Dennis EA, Gilbert ON, et al.: The seroprevalence of hepatitis B surface antigen and human immunodeficiency virus among pregnant women in Anambra State, Nigeria. Shtraz E-medical J 2004, 5(2):1-25.
• [10]Zuckerman JN: Vaccination against hepatitis A and B: development deployment and elusion. Curr Opin Infect Dis 2006, 19(5):456-9.
• [11]Martin-Ancel A, Casas ML, Bonet B: Implication of Post vaccination hepatitis B surface antigenemia in the management of exposure to body fluids. Infect control Hosp Epidemiol 2004, 25(7):611-3.
• [12]MCS: Mayo Clinic Staff. Hepatitis B prevention. Mayo Clinic. http:www.mayoclinic.com/health/hepatitis B/DS webcite
• [13]Onwukeme KE, Uguru VE: Haematological values in pregnancy in Jos. West Afr J Med 1990, 9:70-75.
• [14]Osoagbaka OU, Haruna RH, Anokwuru OC: Observation on some hematological parameters of Nigerian women during pregnancy. J Med Invest Pract 2000, 1:45-48.
• [15]Kei N: Pregnancy and the erythrocyte sedimentation rate. J Immune Based Therapies Vaccines 2004, 2(4):45-57.
• [16]Arinola OG, Obisesan K, Salimonu LS, Onifade R, Afolabi K: Leucocyte phagocytosis and circulation immune complexes in mothers after child birth. West Afr J Med 2004, 23:256-9.
• [17]Pavel A, Tirsia E, Maior E, Cristea A: Detrimental effects of hepatitis B virus infection on the development of product of conception. Virologie 1983, 34:34-40.
• [18]Tse KY, Lo LF, Lao T: The Impact of maternal HBsAg carrier status on pregnancy outcomes: A case–control study. J Hepatol 2005, 43:371-75.
• [19]Nwokedi E, Odimayo MS, Emokpae AM, Yahaya IA, Sadiq MN, Okwori EE: Seroprevalence of hepatitis B surface antigen among patients attending Aminu Kano Teaching Hospital. Kano Niger J Med 2010, 19(4):423-6.
• [20]Olokoba AB, Salawu FK, Danburam A, Desalu OO, Olokoba LB, Wahab KW, Badung LH, Tidi SK, Midala J, Aderibigbe S, Abdulrahman MB, Babalola OM, Abdukkarim A: Viral hepatitides in voluntary blood donors in Yola, Nigeria. Euro J Sci Res 2009, 31(3):329-334.
• [21]Onakewhor JUE, Offor E, Okonofua FE: Maternal and neonatal seroprevalence of hepatitis B surface antigen (HBsAg) in Benin city, Nigeria. J Obs Gynaecol 2001, 21(6):583-586.
• [22]Iwalokun BA, Hodonu SO, Olaleye BM, Olabisi OA: Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos. Afri J Med Med Sci 2006, 35(3):337-43.
• [23]Ajayi AO, Komolafe AO, Ajumobi K: Seroprevalence of hepatitis B surface antigenemia among health care workers in a Nigerian tertiary health institution. Niger J Clin Pract 2007, 10(4):287-9.
• [24]Dawaki SS, Kawo AH: Seroprevalence of hepatitis B Surface antigen among pregnant women. Nig J Microbiol 2006, 20(1):705-709.
• [25]Araoye MO: Sample size determination. Research methodology with statistics for health and social sciences. 2003, 118-121.
• [26]Isselbacher KJ, Wands JR, et al.: Neoplasms of the liver. In Harrison’s Principle of Internal Medicine (12th Edition). Edited by Wilson JD, Braunwald E, Isselbacher K. New York, USA: McGraw-Hill; 1991:1350-1352.
• [27]Miren B, Asun S, Mario S, Enrigue G, Iboy DO, Ramon C: Seroprevalence of hepatitis B and C and human immunodeficiency type 1 virus in a rural population from the Republic of Equatorial Guinea. Trans R Soc Trop Med Hyg 1999, 93:250-252.
• [28]Awosere KE, Arinola OG, Uche LN: Hepatitis B virus seroprevalence among pregnant women. J Med Lab Sc 1999, 3(2):23-27.
• [29]Kong KL, Cho Y, Lee SS: The declining HBsAg carriage rate in pregnant women in Hong Kong. Epidemiol Infect 1997, 199:281-283.
• [30]Agbede OO, Iseniyi JO, Kolawole OM, Ojuawo A: Risk factors and Seroprevalence of hepatits B surface antigenemia in mothers and their pre-school age children in Ilorin, Nigeria. Future Med Therapy 2007, 4(1):67-72.
• [31]Aganga WOM, Akanmu AS, Akinsete A, Njoku OS: Prevalence of hepatitis B surface antigen among women of childbearing age. Afr J Rep 1999, 3(1):45-50.
• [32]Opaleye OO, Zakariyahu TO, Tijani BA, Bakarey AS: HBV, HCV co-infection among blood donors in Nigeria. Indian J Pathol Microbiol 2010, 53:182-3.
• [33]Soxhami RL, Moxhan J: Textbook of Medicine (1st Ed). Churchill Livingstone city, United Kingdom: Longman Group Publishers; 1991:634-635.
• [34]Duncan ME, Tibaus G, Pelger A: Prevalence and significance of sexually transmitted diseases among women. Ethiop J Health Dev 1995, 9:31-40.
• [35]Maddawa V, Burgress C, Drucker E: Epidemiology of Chronic Hepatitis C infection in sub-Saharan Africa. Lancet Infect 2002, 2:293-302.
• [36]Alter HJ, Blumberg BS: Further studies on a new human isoprecipitin system (Australia antigen). Blood 1966, 27(3):297-309.
• [37]Shale MJ: The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009, 92(1):61-77.
• [38]Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, Sankale J, Ekong E, Murphy R, Kanki P, Thio CL: Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009, 49(8):1268-1273.
• [39]Nakamura K, Yuh K, Sugyo S, Shijo H, Kimura N, Okumura M: Apoptosis observed in peripheral T lymphocytes from patients with chronic hepatitis B. Gastroenterology 1996, 111:156-164.
• [40]Raptopoulou-Gigi M, Orphanou-Koumerkeridou H, Lagra F: Possible mechanisms underlying peripheral lymphocyte activation in chronic liver disease and asymptomatic HBsAg carriers. Allergol Immunopathol (Madr) 1989, 17:145-148.